Chaperone Heat Shock Protein 90 Mobilization and Hydralazine Cytoprotection against Acrolein-Induced Carbonyl Stress

Philip C. Burcham, Albert Raso, and Lisa M. Kaminskas
Pharmacology, Pharmacy and Anaesthesiology Unit, School of Medicine and Pharmacology, University of Western Australia, Nedlands, Australia (P.C.B., A.R.); and Discipline of Pharmacology, School of Medical Sciences, University of Adelaide, Adelaide, Australia (L.M.K.)

Received March 28, 2012; accepted August 3, 2012

ABSTRACT
Toxic carbonyls such as acrolein participate in many degenerative diseases. Although the nucleophilic vasodilatory drug hydralazine readily traps such species under "test-tube" conditions, whether these reactions adequately explain its efficacy in animal models of carbonyl-mediated disease is uncertain. We have previously shown that hydralazine attacks carbonyl-adducted proteins in an "adduct-trapping" reaction that appears to take precedence over direct "carbonyl-sequestering" reactions, but how this reaction conferred cytoprotection was unclear. This study explored the possibility that by increasing the bulkiness of acrolein-adducted proteins, adduct-trapping might alter the redistribution of chaperones to damaged cytoskeletal proteins that are known targets for acrolein. Using A549 lung adenocarcinoma cells, the levels of chaperones heat shock protein (Hsp) 40, Hsp70, Hsp90, and Hsp110 were measured in intermediate filament extracts prepared after a 3-h exposure to acrolein. Exposure to acrolein alone modestly increased the levels of all four chaperones. Coexposure to hydralazine (10–100 μM) strongly suppressed cell ATP loss while producing strong adduct-trapping in intermediate filaments. Most strikingly, hydralazine selectively boosted the levels of cytoskeletal-associated Hsp90, including a high-mass species that was sensitive to the Hsp90 inhibitor 17-N-allylamino-17-demethoxygeldanamycin. Biochemical fractionation of acrolein- and hydralazine-treated cells revealed that hydralazine likely promoted Hsp90 migration from cytosol into other subcellular compartments. A role for Hsp90 mobilization in cytoprotection was confirmed by the finding that brief heat shock treatment suppressed acute acrolein toxicity in A549 cells. Taken together, these findings suggest that by increasing the steric bulk of carbonyl-adducted proteins, adduct-trapping drugs trigger the intracellular mobilization of the key molecular chaperone Hsp90.

Introduction
Many degenerative diseases are accompanied by an overproduction of reactive carbonyl compounds such as acrolein and 4-hydroxynonenal (Dalle-Donne et al., 2006; Lopachin et al., 2007). As strong electrophiles, these species deplete GSH and attack the proteome to form deleterious protein adducts (West and Marnett, 2006; Negre-Salvayre et al., 2008). Seeking to offset such damage, researchers have explored the use of nucleophilic drugs to scavenge "free" carbonyls within cells, attempting to attenuate macromolecular adduction and any accompanying toxicity (Aldini et al., 2007, 2011a; Burcham, 2008). Agents that have attracted attention as “carbonyl scavengers” include the neuroprotectant evaradone (Aldini et al., 2010), the antidepressant phenelzine (Wood et al., 2006), the hypoglycemic metformin (Ruggiero-Lopez et al., 1999), the antimicrobial isoniazid (Galvani et al., 2008), the dipeptide carnosine (Aldini et al., 2011b), the vasodilator hydralazine (Burcham et al., 2000), the antioxidant ascorbate (Kesinger et al., 2010), and various biogenic polyphenolic compounds (Zhu et al., 2009). For some of these agents, interpreting their in vivo efficacy is complicated by "secondary" pharmacological actions unrelated to carbonyl-sequestering reactivity; hence, further medicinal chemistry workup may be needed to derive useful "pharmacologically inert" carbonyl scavengers (Burcham et al., 2008; Bouguerne et al., 2011).

Among the strongest nucleophiles in clinical use, the antihypertensive hydralazine efficiently traps numerous

ABBREVIATIONS: IF, intermediate filament; Hsp, heat shock protein; PMSF, phenylmethanesulfonyl fluoride; 17-AAG, 17-N-allylamino-17-demethoxygeldanamycin; BPBS, Dulbecco’s phosphate-buffered saline; FBS, fetal bovine serum; PBS, phosphate-buffered saline; PAGE, polyacrylamide gel electrophoresis.
carbonyl compounds within the plasma of human recipients (Reece, 1981). Under test-tube or cell-free conditions, hydralazine displays pronounced reactivity toward acrolein (Kaminskas et al., 2004a). Low hydralazine concentrations also block the toxicity of acrolein in diverse cell types including hepatocytes, neuronal cells, and lung epithelial cells (Liuy-Snyder et al., 2006; Burcham et al., 2007; Truong et al., 2009). Protective efficacy for hydralazine has also been shown in several animal models of carbonyl-mediated pathologies, including diabetic nephropathy, allyl alcohol hepatotoxicity, spinal cord injury, atherosclerosis, and experimental autoimmune disease (Nangaku et al., 2003; Kaminskas et al., 2004b; Vindis et al., 2006; Hamann et al., 2008; Leung et al., 2011). The mechanism(s) underlying drug efficacy in these models is unclear because the direct reactivity of hydralazine with electrophilic carbonyls may be constrained within biological systems. For example, in a hepatocyte model in which acrolein was generated enzymatically from allyl alcohol, hydralazine prevented cell death without lowering either extra- or intracellular “free acrolein” levels or the formation of protein adducts (Burcham et al., 2006). Others have also observed that hydralazine fails to block protein carbonylation in cultured cells, concluding instead that antioxidant actions mediate the cytoprotection (Mehta et al., 2009; Zheng and Bizzozero, 2010).

Our laboratory has described a distinctive “protein-adduct trapping” reaction for hydralazine that involves facile reactivity with Michael adducts formed by acrolein at nucleophilic sites in proteins (Burcham et al., 2004). Using Western blotting, intense adduct trapping was detected in allyl alcohol-treated hepatocytes upon treatment with protective hydralazine concentrations (Burcham et al., 2004). Strong adduct trapping also accompanied hydralazine protection against allyl alcohol hepatotoxicity in mice (Kaminskas et al., 2004b). How adduct trapping might confer protection was unclear, but one possibility was that hydralazine inactivated carbonyl-retaining Michael adducts before their participation in cross-linking with neighboring macromolecules (Burcham and Pyke, 2008). Contrary to this expectation however, hydralazine failed to block acrolein-induced protein cross-linking in cultured lung cells (Burcham et al., 2007). Other pathways whereby adduct trapping might confer cytoprotection awaited exploration.

We identified vimentin and other intermediate filaments (IFs) as targets for acrolein modification in A549 lung cells (Burcham et al., 2010). These key cytoskeletal constituents provide tensile strength to cell networks and serve as scaffolds for diverse cell-signaling molecules (Kim and Coulombe, 2007). Consistent with the role of chaperones in helping cells withstand protein-modifying stresses, acrolein exposure triggered the redistribution of chaperones heat shock protein (Hsp) 40, Hsp70, Hsp90, and Hsp110 to IF fractions in A549 cells (Burcham et al., 2010). Moreover, the efficient acrolein scavenger bisulfite simultaneously blocked IF modification and Hsp90 redistribution, suggesting chaperone mobilization was a consequence of IF damage (Burcham et al., 2010).

This study sought to clarify the mechanisms underlying hydralazine cytoprotection against carbonyl stress. An initial goal was to determine whether antioxidant actions might explain the cytoprotective properties of hydralazine. To supplement this approach, we explored whether the covalent incorporation of hydralazine into acrolein-adducted proteins via adduct-trapping might contribute to cytoprotection by assessing the “reversibility” of the protective mechanism. Finally, we explored whether hydralazine alters the redistribution of molecular chaperones to damaged IF during acrolein toxicity. Taken together, these experiments revealed that rather than its cytoprotective efficacy being attributable to antioxidant actions alone, they instead involve a “boost” in the subcellular availability of free Hsp90 that occurs subsequent to adduct-trapping reactions with carbonyl-adducted proteins.

Materials and Methods

Reagents. Rabbit anti-Hsp90 (detects both α and β isoforms) and anti-Hsp70 were purchased from Cell Signaling Technology (Danvers, MA). Hydralazine hydrochloride, phenylmethanesulfonyl fluoride (PMSF), N-tosyl-L-arginine methylester, 17-N-allylaminomethyl-17-deoxyxygeldanamycin (17-AAG), goat anti-vimentin serum, rabbit anti-dinitrophenol, anti-Hsp40, and anti-Hsp110 sera were obtained from Sigma-Aldrich (St. Louis, MO). Peroxidase-coupled goat anti-rabbit IgG was purchased from Thermo Fisher Scientific (Waltham, MA). Acrolein was supplied by Enzo Life Sciences, Inc., Lausen, Switzerland. Dulbecco’s phosphate-buffered saline (DPBS; glucose and pyruvate-containing) was supplied by Invitrogen Australia (Mount Waverly, Victoria, Australia).

Cell Culture. All acrolein-containing solutions were prepared in a fume hood. Human A549 adenocarcinoma lung cells were grown in F12 nutrient mixture supplemented with 10% fetal bovine serum (FBS; v/v) and gentamicin (100 μg/ml) until confluence was attained. The cells were harvested by trypsin-EDTA digestion and resuspended in F12 media supplemented with 0.5% FBS before they were plated in 1.4-ml volumes on six-well plates at a density of 0.6 × 106 cells/well. The plates were then maintained overnight in 5% CO2 in a humidified environment at 37°C. Cells were rinsed twice with DPBS before commencing exposure to acrolein in DPBS at a typical final concentration of 150 μM. The use of DPBS helped minimize side-reactions of acrolein with nucleophilic media constituents (Thompson and Burcham, 2008). All acrolein solutions were prepared immediately before use. In experiments in which the effect of drug treatment during the “postadduction phase” of toxicity was studied, cells were exposed to 75 μM acrolein in the presence and absence of hydralazine (100 μM) for 60 min, after which they were rinsed twice with DPBS to remove unreacted aldehyde. Fresh solutions of F12 media containing 0.5% FBS with or without hydralazine supplementation (μM) were then added before the plates were returned to the incubator. ATP determinations were made after a subsequent 3-h incubation.

Biochemical Procedures. Cell ATP levels were measured as indicators of viability using a Promega CellTiter-Glo Luminescent Cell Viability assay kit (Promega, Madison, WI) according to the manufacturer’s protocols. Luminescence readings were taken using a POLARtet Optima microplate reader (BMG Labtech GmbH, Offenburg, Germany).

Preparation of subcellular fractions (membrane, cytosol, cytoskeletal, and nuclear) was achieved using a Qproteome Cell Compartment Kit (QIAGEN, Doncaster, Victoria, Australia). Alternatively, to prepare IF extracts directly, A549 monolayers grown on 12-cm2 flasks were rinsed three times with Ca2+- and Mg2+-free phosphate-buffered saline (PBS) before a 10-ml volume of cell lysis solution was added to each dish (Ca2+- and Mg2+-free PBS containing 0.6 M KCl, 1% Triton X-100, 10 mM MgCl2, 1% β-mercaptoethanol, 1 mM PMSF, and 0.5 mg/ml P-tosyl-L-arginine methylester) (Burcham et al., 2010). DNase I was added to a concentration of 0.5 mg/ml, and the dishes were placed on ice for 5 min. The suspensions were then transferred to polypropylene tubes and centrifuged at 900g for 10 min at 4°C, after which the supernatants were discarded. The IF-containing pellets were then washed via one round of centrifugation...
(3 min, 2000 g) in Ca²⁺- and Mg²⁺-free PBS containing 0.1 mM PMSF and 1% β-mercaptoethanol before final resuspension in 75 μl urea (6 M). Protein concentrations in 5-μl aliquots were then estimated using the Pierce BCA Protein Assay Kit (Thermo Fisher Scientific).

Western Blotting. After exposure to acrolein or drugs, cells were rinsed with DPBS before proteins were extracted by adding 50 μl of 6 M urea to each well. Ten-microliter aliquots were assayed for protein content, and then lysate volumes containing 15 μg of protein were treated with an equal volume of carbonyl-derivatizing solution [0.5%, 2,4-dinitrophenyl hydrazine (w/v) in 10% trifluoroacetic acid (v/v)]. Subsequent sample preparation steps as well as electrophoresis and Western blotting conditions were performed as outlined previously (Burcham et al., 2007). Densitometry was performed on chemiluminescence images using Kodak Molecular Imaging software (versus 4.01) (Carestream Health, Rochester, NY). Images were either collected using photographic film (see Figs. 3, 4, 5, and 7) or a GE ImageQuant LAS4000 imager (GE Healthcare, Chalfont St. Giles, Buckinghamshire, UK) (see Figs. 6, 8, and 9). Adduct trapping within IF proteins was detected via Western blotting using rabbit antiserum raised against acrolein/hydralazine-modified carrier protein as described previously (Burcham et al., 2004).

Hsp90 Protein Capture. A protein-capture technique using a biotin-labeled analog of the Hsp90 inhibitor geldanamycin was used to selectively recover Hsp90 from A549 cells (Connor et al., 2011). Cell lysates were prepared using the same lysis buffer described previously (Connor et al., 2011). After protein determination using the BCA protein assay (Thermo Fisher Scientific), coupled to an Applied Biosystems 4000 Q Trap mass spectrometer (Applied Biosystems, Foster City, CA). Tryptic peptides were loaded on a 3-μm C18 PepMap100 column (Thermo Fisher Scientific) and eluted using water/acetonitrile/0.1% formic acid (v/v/v). Proteins of interest were identified within peptide mass spectra using Mascot search database software (Matrix Science, Inc., Boston, MA) to interrogate the LudwigNR database (human protein sequence database, January 2012, 140,018 sequences) (http://www.ncpf.edu.au; Ludwig Institute for Cancer Research, Melbourne, VIC, Australia) .

Hyperthermic Stress. A549 cells maintained in F12 media supplemented with 0.5% FBS [grown on either 96-well plates or securely capped culture flasks (25 cm²)] were immersed for 60 min in water baths held at 43, 44, or 45°C (Han et al., 2008). Controls were maintained at 37°C in a conventional humidified 5% CO₂ incubator. After heat treatment, IFs were extracted from the 25-cm² flask cell monolayers using the detergent-based procedure described above under Biochemical Procedures. IF extracts (50 μg protein/lane) were then resolved via SDS-PAGE before transfer to nitrocellulose followed by immunoblotting with anti-Hsp90 serum as outlined above under Western Blotting. Membranes were then stripped and reprobed with anti-vimentin serum (the IF vimentin served as a loading control in this experiment). Heat-pretreated cells grown on 96-well plates were briefly rinsed with DPBS before they were incubated for 3 h in DPBS containing 150 μM acrolein. Cell ATP levels were then estimated using the Promega CellTiter-Glo kit method outlined above (Promega) under Biochemical Procedures.

Antioxidant Assays. The antioxidant efficacy of hydralazine and reference compounds was compared in a cell-free system using the galvinoxyl assay (Shi et al., 2001). Galvinoxyl was dissolved in methanol, whereas stock solutions of reference compounds were prepared in acetonitrile. Galvinoxyl (1 ml of a 5-μM solution) was added to a 1-cm quartz cuvette, and reactions were started by adding 10-μl volumes of test compounds to yield a final concentration of 2.5 μM. Galvinoxyl consumption was monitored at room temperature using a Hitachi U-2000 UV/VIS spectrophotometer (429-nm wavelength) (Hitachi Software Engineering, Yokohama, Japan). Lipid peroxidation in cell monolayers was assessed using the thiobarbituric acid assay (Nicholls-Grimsen et al., 2000).

Results. Data were analyzed via one-way analysis of variance using SigmaStat for Windows (version 3.5) (Systat Software, Inc., San Jose, CA). The post hoc tests used to detect differences between treatment groups are specified in the legends of the relevant figures.

Consistent with the induction of acute cytotoxicity, cell ATP levels were decreased by 60% after a 4-h exposure to acrolein (Fig. 1). Treatment with hydralazine (10–300 μM) strongly attenuated ATP loss (Fig. 1). Because the protective efficacy of hydralazine against chemically induced toxicity was suggested to involve antioxidant actions (Mehta et al., 2009), the galvinoxyl assay was used to compare the radical-trapping activity of hydralazine with that of established antioxidants (Fig. 2A). Concurring with observations made by Mehta et al. (2009) using cultured cells, hydralazine displayed strong radical-quenching activity toward galvinoxyl radicals, exhibiting activity that matched or exceeded that of ascorbate or the vitamin E analog 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox; Hoffmann-La Roche, Nutley, NJ) (Fig. 2A). Consistent with these properties, hydralazine suppressed the formation of lipid peroxidation products during a 3-h exposure of A549 cells to acrolein, showing comparable antioxidative efficacy in this respect to 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (Trolox) (Fig. 2B). In contrast to hydralazine however, 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid did not prevent the ATP depletion that accompanied acrolein exposure, whereas ascorbate actually enhanced ATP loss (Fig. 2C). Ascorbate also increased the formation of this thiobarbituric acid reactive substances (data not shown). These findings suggest antioxidant properties alone are insufficient to suppress acute acrolein-induced toxicity in A549 cells.

Fig. 1. Hydralazine prevented the loss of cell ATP that accompanied a 4-h exposure to acrolein (ACR, 150 μM) in A549 lung cells. Each data point is the mean ± S.E. of four independent experiments.
The reversibility of hydralazine cytoprotection was assessed in the expectation that if the covalent incorporation of hydralazine into cell proteins via adduct trapping contributed to cytoprotection, cell viability would persist if hydralazine (HYD) concentrations tested, each of which also prevented the loss of cell ATP (refer to Fig. 1). Although hydralazine displays excellent reactivity toward "free" unsaturated aldehydes in model in vitro systems, it is unclear whether these properties apply within complex intracellular environments (Burcham and Pyke, 2006). To address this issue in the lung cell model used in the present study, we determined whether hydralazine suppressed acrolein-induced adduction of IFs, which are known targets for acrolein in lung cells (Burcham et al., 2010). Concurring with earlier work that ruled out a role for carbonyl scavenging in cytoprotection, the lowest, fully protective concentrations of hydralazine (Fig. 1) protected neither vimentin nor three keratin targets against acrolein adduction (Fig. 3A). Only the highest hydralazine concentration tested, 300 μM, strongly inhibited IF modification (Fig. 3A). This suggests that within the intracellular environment, reactions between free acrolein and nucleophilic target proteins proceed rapidly, and that hydralazine suppresses these reactions only when present at very high concentrations.

Although low hydralazine concentrations failed to prevent IF carbonylation, under these experimental conditions, clear adduct trapping did occur on IF targets (Fig. 3B). Indeed, adduct trapping was detected within each of the main IF targets for acrolein in A549 cells, namely vimentin, keratin-7, keratin-8, and keratin-18 (Fig. 3B). The identity of these four IF targets was established previously via liquid chromatography/mass spectrometry (Burcham et al., 2010). Consistent with associations of adduct trapping with cytoprotection in other experimental systems (Burcham et al., 2004; Kaminskas et al., 2004b), adduct trapping was evident at all hydralazine concentrations tested of protective compounds. D, the cytoprotection afforded by hydralazine against acrolein-induced ATP loss was not lost upon washing cells and subsequent incubation in drug-free media. See Materials and Methods for experimental details. Each data point is the mean ± S.E. of four independent experiments. *p < 0.05; C, Student-Newman-Keuls test and D, Dunnett’s test). HYD, hydralazine; ASC, ascorbic acid; TROL, Trolox; ACR, acrolein.

The reversibility of hydralazine cytoprotection was assessed in the expectation that if the covalent incorporation of hydralazine into cell proteins via adduct trapping contributed to cytoprotection, cell viability would persist if hydralazine-containing media was removed. Thus, after a 60-min concurrent exposure to acrolein in the presence and absence of hydralazine, the culture medium was removed, and monolayers were rinsed twice with buffered saline before they were incubated for a further 3 h in either hydralazine-containing or drug-free media (Fig. 2D). Consistent with the covalent incorporation of hydralazine into damaged proteins (i.e., adduct trapping) participating in cytoprotection, comparable protection was seen in washed cells maintained in drug-free media during the postadduction phase as in cells that were continuously exposed to hydralazine (Fig. 2D).
To determine whether hydralazine altered these responses, Western blotting was used to monitor chaperone levels in IF fractions extracted from A549 cells after a 3-h exposure to acrolein in the presence and absence of hydralazine (Fig. 4). As in prior work, acrolein alone increased IF-associated levels of Hsp40, Hsp70, Hsp90, and Hsp110 relative to controls or cells that were treated with hydralazine only (Fig. 4, A–D). In the case of Hsp70 and Hsp110, the lowest concentrations of hydralazine did not alter IF-associated chaperone levels relative to the changes that accompanied exposure to acrolein alone (Fig. 4, B and D). In contrast, hydralazine elicited a concentration-dependent decrease in the levels of IF-associated Hsp40, with the 100-µM concentration suppressing Hsp40 levels below detectable levels to resemble controls (Fig. 4A).

The effects of hydralazine on Hsp90 mobilization to damaged IF were especially striking (Fig. 4C; the results obtained during densitometry of replicate experiments are shown in Fig. 4, E and F). Compared with the modest increases in IF-associated Hsp90 induced by acrolein alone, the presence of hydralazine strongly boosted Hsp90 mobilization (Fig. 4C). This effect was evident in levels of monomeric Hsp90 as well as a high-mass oligomeric Hsp90 species (~300 kDa) we observed previously in acrolein-exposed cells (Burcham et al., 2007, 2010). Because high-mass species are known to form when Hsp90 catalysis occurs in the presence of cross-linking agents (Vaughan et al., 2009), this finding suggests hydralazine boosted the intracellular availability of Hsp90 together with its catalytic activity toward damaged protein substrates. Concurring with the strong protection against ATP loss afforded by 10 and 30 µM hydralazine in Fig. 1, the effects of hydralazine on the redistribution and activation of Hsp90 were near maximal at the lowest drug concentrations tested (Fig. 4C).

The concentration dependence of drug-induced changes in IF-associated Hsp90 levels was investigated in cells exposed to a range of acrolein concentrations in the presence of 30 µM hydralazine (Fig. 5A). The 3-h treatment with hydralazine elicited an increase in the levels of monomeric and high-mass Hsp90 at the top two acrolein concentrations, 100 and 150 µM (Fig. 5A). Study of the time course of Hsp90 mobilization to IF indicated this response was rapid and essentially maximal within 1 h of commencing exposure to acrolein and hydralazine (Fig. 5B). This suggests the effect of hydralazine involved boosted mobilization of existing Hsp90, rather than an activation of chaperone synthesis as per the classic heat shock response (i.e., activation of heat shock factor 1-driven transcriptional activity) that is expected to occur over a longer experimental time frame.

Reflecting its ability to inhibit the catalytic cycle of Hsp90 by targeting the ATP-binding domain of the chaperone complex, the Hsp90 inhibitor 17-AAG abolished the increase in IF-associated Hsp90 mobilization (Fig. 4C).
concentration dependence in the formation of trapped adducts with endogenous proteins were not detected in hydralazine-adducted proteins occurred in this compartment. Reactions right), indicating drug reactions with endogenous carbonyl-cytokeletal and nuclear fractions occurred above that elicited by Hsp90 levels (Fig. 7A, left). The chaperone per se (Fig. 6B).

To characterize drug-induced changes in subcellular Hsp90 distribution at the biochemical level, cells were coexposed to acrolein and a range of hydralazine concentrations for 3 h before cellular fractionation was performed to obtain cytosolic, nuclear, cytoskeletal, and membrane fractions (Fig. 7). In keeping with literature expectations, Hsp90 was primarily located within cytosol of unstressed and hydralazine-treated control cells (Fig. 7A, left). Upon exposure to acrolein in the presence of hydralazine, a pronounced redistribution of Hsp90 to the nuclear and cytoskeletal fractions occurred above that elicited by acrolein alone, with the levels of both monomeric and high-mass Hsp90 increased by the drug (Fig. 7, B and C, left). The chaperones that relocated to these fractions most likely originated in cytosol, where hydralazine treatment elicited a clear reduction in Hsp90 levels (Fig. 7A, left).

Western blot analysis of cell extracts for the presence of hydralazine-labeled species revealed adduct trapping occurred in all fractions to which Hsp90 was mobilized (Fig. 7, A–D, right). Hydralazine also participated in “spontaneous” adduct-trapping reactions with two cytosolic proteins in controls that were not knowingly exposed to acrolein (Fig. 7A, right), indicating drug reactions with endogenous carbonyl-adducted proteins occurred in this compartment. Reactions with endogenous proteins were not detected in hydralazine-treated controls in the other cell fractions.

In cells concurrently exposed to acrolein and hydralazine, concentration dependence in the formation of trapped adducts was evident over the 10 to 100 µM drug concentration range within cytosolic (Fig. 7A), nuclear (Fig. 7C), and membrane fractions (Fig. 7D). A ~35-kDa protein sustained strong, concentration-dependent adduct trapping in the membrane fractions of acrolein/hydralazine-exposed cells (Fig. 7D, right). Concentration dependence was less obvious within cytoskeletal extracts (Fig. 7B), where adduct trapping appeared saturated at the lowest drug concentration tested (10 µM) for a ~50 kDa protein (highlighted with an arrow on Fig. 7B, right). This strong band may reflect adduct trapping on vimentin or other IF proteins that are major cytoskeletal targets for acrolein within A549 cells (Burcham et al., 2010). Given that Hsp90 mobilization was essentially maximal at the 10-µM concentration (Fig. 4, C, E, and F), this suggests adduct trapping on IF may facilitate the mobilization of subcellular Hsp90 by hydralazine.

Seeking to clarify the mechanisms underlying drug-induced Hsp90 redistribution, a new protein-capture technique using a biotin-labeled analog of the Hsp90 inhibitor geldanamycin was used to recover Hsp90 from unfraccionated cell lysates prepared after a 3-h exposure of A549 cells to acrolein in the presence and absence of hydralazine (Fig. 8). Western blot analysis of the captured proteins using anti-Hsp90 antiserum revealed that, consistent with the conclusion that hydralazine does not induce Hsp90 expression at the protein level, no changes were evident in the levels of monomeric chaperone in any of the treatment groups (Fig. 8A). A conspicuous high-mass Hsp90-containing band that exhibits similar migration properties during SDS-PAGE to the high-mass Hsp90 that accompanied coexposure to acrolein and hydralazine (Fig. 6A). In contrast, 17-AAG had no effect on the redistribution of monomeric Hsp90 to damaged IF (Fig. 6A). The Hsp90 inhibitor also failed to substantially attenuate hydralazine-induced protection against cellular ATP loss (Fig. 6B), suggesting the cytoprotection might involve boosted redistribution of monomeric Hsp90 to damaged proteins rather than any drug-induced increase in the catalytic activity of the chaperone in any of the treatment groups (Fig. 8A). A comparison of acrolein- and hydralazine-treated cell ATP (% control) (data not shown) revealed that, consistent with the conclusion that hydralazine does not induce Hsp90 expression at the protein level, no changes were evident in the levels of monomeric chaperone in any of the treatment groups (Fig. 8A). A conspicuous high-mass Hsp90-containing band that exhibits similar migration properties during SDS-PAGE to the high-mass Hsp90 that accompanied coexposure to acrolein and hydralazine (Fig. 6A). In contrast, 17-AAG had no effect on the redistribution of monomeric Hsp90 to damaged IF (Fig. 6A). The Hsp90 inhibitor also failed to substantially attenuate hydralazine-induced protection against cellular ATP loss (Fig. 6B), suggesting the cytoprotection might involve boosted redistribution of monomeric Hsp90 to damaged proteins rather than any drug-induced increase in the catalytic activity of the chaperone in any of the treatment groups (Fig. 8A). A comparison of acrolein- and hydralazine-treated cell ATP (% control) (data not shown) revealed that, consistent with the conclusion that hydralazine does not induce Hsp90 expression at the protein level, no changes were evident in the levels of monomeric chaperone in any of the treatment groups (Fig. 8A). A conspicuous high-mass Hsp90-containing band that exhibits similar migration properties during SDS-PAGE to the high-mass Hsp90 that accompanied coexposure to acrolein and hydralazine (Fig. 6A). In contrast, 17-AAG had no effect on the redistribution of monomeric Hsp90 to damaged IF (Fig. 6A). The Hsp90 inhibitor also failed to substantially attenuate hydralazine-induced protection against cellular ATP loss (Fig. 6B), suggesting the cytoprotection might involve boosted redistribution of monomeric Hsp90 to damaged proteins rather than any drug-induced increase in the catalytic activity of the chaperone in any of the treatment groups (Fig. 8A).
mass species detected within IF extracts in the previous experiments was recovered from acrolein/hydralazine-treated cells using the Hsp90 protein-capture methodology (Fig. 8A). Analysis of this recovered high-mass protein sample via electrospray ionization-mass spectrometry confirmed the presence of the α and β forms of Hsp90, but insufficient novel peptides were identified to allow identification of any putative protein cross-linking participants (data not shown).

Analysis of captured protein samples using the antibody against hydralazine/acrolein-labeled proteins revealed that adduct trapping occurred in both the monomeric and high-mass Hsp90 bands (Fig. 8B).

To test whether acute Hsp90 mobilization protects against acrolein toxicity, A549 cells were subjected to a brief 60-min heat shock treatment at 43, 44, or 45°C before commencing acrolein exposure (Fig. 9). Western blot analysis of IF extracts prepared from cells immediately after the heat treatments revealed Hsp90 mobilization to IF occurred only at the highest temperature tested (45°C; Fig. 9A). Measurement of ATP levels in control- and heat-treated cells after a subsequent 3-h exposure to 150 µM acrolein revealed that only the 45°C temperature fully protected against ATP loss (Fig. 9E).

### Discussion

The present findings reveal an unexpected consequence accompanying exposure of oxidatively stressed cells to nucleophilic carbonyl-trapping drugs. Using hydralazine, an
A Captured Protein: Hsp90

<table>
<thead>
<tr>
<th></th>
<th>ACR (µM)</th>
<th>0</th>
<th>0</th>
<th>150</th>
<th>150</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HYD (µM)</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

B Captured Protein: Adduct-Trapping

<table>
<thead>
<tr>
<th></th>
<th>ACR (µM)</th>
<th>0</th>
<th>0</th>
<th>150</th>
<th>150</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HYD (µM)</td>
<td>0</td>
<td>100</td>
<td>0</td>
<td>100</td>
</tr>
</tbody>
</table>

Fig. 8. Western blot analysis confirms drug-induced adduct trapping occurs on monomeric and high-mass forms of Hsp90 captured from acrolein (ACR) and hydralazine (HYD)-treated A549 cells using a geldanamycin-biotin tag. A, hydralazine (100 µM) promotes the formation of high-mass Hsp90 in acrolein-exposed cells. B, adduct trapping is present on Hsp90 recovered from hydralazine-treated cells. A large species that appears to comigrate with the Hsp90 reaction product identified within IF extracts in the earlier experiments is highlighted with an arrow. The immunoblots shown are representative of two experimental replicates.

Fig. 9. Hyperthermia-induced Hsp90 mobilization suppresses the acute toxicity of acrolein. A, temperature-dependent redistribution of Hsp90 to IF extracts (50 µg protein/lane) after a 60-min incubation of A549 cells at the respective temperatures shown. The IF constituent vimentin served as loading control. ATP levels in cells exposed to acrolein for 3 h after a prior 60-min heat pretreatment at either 37 (B), 43 (C), 44 (D), or 45°C (E). See Materials and Methods for experimental details. Each data point is the mean ± S.E. of three to four independent experiments. *, a significant difference from control (p < 0.05, unpaired t test).

Although the precise mechanisms underlying hydralazine-induced Hsp90 redistribution are unclear, a role for adduct trapping seems likely (Fig. 10). We previously used mass spectrometry to study the reaction of hydralazine with an acrolein-modified peptide, confirming that hydralazine reacts with carbonyl-retaining adducts to form multiple hydra-zones, which we collectively termed “trapped adducts” (Burcham et al., 2004). Such reactivity with acrolein-derived protein adducts sets hydralazine apart from other carbonyl scavengers (Burcham et al., 2004). Moreover, using a rabbit antibody raised against hydralazine/acrolein-modified protein, we detected strong adduct trapping in hepatocytes that were concurrently exposed to low concentrations of hydralazine and the acrolein precursor allyl alcohol (Burcham et al., 2004). This antibody also revealed intense adduct trapping during acrolein-mediated hepatotoxicity in mice that received hepatoprotective doses of hydralazine (Kaminskas et al., 2004b). Precisely how adduct trapping might confer such protection was unclear, because the expectation that this mechanism would suppress intramolecular protein cross-linking during acrolein toxicity was not confirmed in cellular studies (Burcham et al., 2007).

Although this study identifies Hsp90 mobilization as a novel mechanism accompanying adduct trapping by hydralazine, it is interesting that we failed to detect this mechanism previously when the effect of acrolein and hydralazine on Hsp90 expression was studied in unfractionated cell lysates (Burcham et al., 2007). Thus, drug-induced Hsp90 mobilization became evident only after fractionation techniques were used to prepare cytoskeleton-enriched cell extracts. These observations form the basis of our hypothesis concern-
that the suppression of acute cell death is associated with enhanced cellular availability of Hsp90 per se. Hsp90 complexes are thought to exist in two main forms, namely a "proteasome-targeting" species that involves the ancillary proteins Hsp70 and Hsp70-Hsp90 organizing protein and a "stabilizing" form that involves cdc37 and p23 (Sullivan et al., 1997; Aridon et al., 2011). More work is needed to clarify the protein composition and cellular fate of agglomerates that form upon recruitment of Hsp90 to the "trapped adduct-containing complexes" of hydralazine, which is the formation of these known Hsp90-containing complexes. Such research should also help identify the protein constituents of the high-mass Hsp90-containing species, which is a conspicuous product of hydralazine cytoprotection against carbonyl stress.

The finding that the chaperone redistribution elicited by hydralazine in acrolein-exposed cells was selective for Hsp90 is intriguing given that Hsp90 is typically highly expressed and may be modest. For example, the Michael adduct formed on reaction of acrolein with protein nucleophiles confers an additional mass of 56 Da, yet subsequent reaction with hydralazine forms a trapped adduct with a supplementary mass of 198 Da (Burcham et al., 2004). Within cells, proteins containing these bulkier "drug-trapped" lesions may be more readily recognized by damage response pathways such as the Hsp90 chaperone pathway because the larger lesions may elicit more pronounced conformational changes that expose internal hydrophobic domains that flag chaperone recruitment. This scenario concurs with current theories concerning client recognition by Hsp90 in which changes in the conformation or stability of target proteins are considered more important than the exposure of specific recognition motifs such as that which occurs for Hsp70 (Taipale et al., 2010).

The fact that the Hsp90 inhibitor 17-AAG blocked the formation of a high-mass form of Hsp90, which was strongly induced by hydralazine yet failed to attenuate either the mobilization of monomeric Hsp90 to IF or the cytotoxicity that was conferred by hydralazine (Fig. 6B), may suggest that oxidative stress are typically small electrophiles, the chemical structures of species formed during adduction by endogenous electrophiles such as acetaminophen, ipomeanol, furosemide, and bromobenzene, the ability of xenobiotics to form protein-modifying intermediates is typically viewed as a precursor to such unwanted outcomes as impaired macromolecular function or haptenization of tissue proteins (Mitchell et al., 1973). Although this paradigm has strongly influenced drug discovery and development, many exceptions exist to the rule that "protein adduction by drugs equals toxicity." Indeed, the formation of stable adducts with target proteins underlies the efficacy of many medicines, including aspirin, rasagilin, phenoxybenzamine, esomprazole, clopidogrel, and gemcitabine (Singh et al., 2011). After classic studies on the metabolic activation of such toxicants as acetaminophen, ipomeanol, furosemide, and bromobenzene, the ability of xenobiotics to form protein-modifying intermediates is typically viewed as a precursor to such unwanted outcomes as impaired macromolecular function or haptenization of tissue proteins (Mitchell et al., 1973). Although this paradigm has strongly influenced drug discovery and development, many exceptions exist to the rule that "protein adduction by drugs equals toxicity." Indeed, the formation of stable adducts with target proteins underlies the efficacy of many medicines, including aspirin, rasagilin, phenoxybenzamine, esomprazole, clopidogrel, and gemcitabine (Singh et al., 2011). Typically, covalent drugs are assigned to one of two classes: those containing pre-existing electrophilic functionality within the parent structure (e.g., amoxicillin) and those that undergo biotransformation to electrophilic species (e.g., acetaminophen). Our findings suggest a third category comprising nucleophilic drugs that react with electrophilic functionalities that are introduced into proteins during adduction by endogenous electrophiles (e.g., acrolein). Given the plethora of bifunctional electrophilic carbonyls that form during normal metabolism, reactions of adducted proteins with circulating nucleophilic drugs might be more extensive than currently realized.

Given the potential significance of this novel pharmacological mechanism to a range of diseases that involve carbonyl
stress, several important avenues of future research require exploration. For example, it is unclear whether the Hsp90 redistribution elicited by hydralazine occurs selectively in response to adduct trapping on specific proteins or whether chaperone mobilization occurs indiscriminately throughout the entire cell. The use of immunocytochemical imaging to monitor changes in subcellular Hsp90 localization should resolve such questions and also clarify whether drug-induced chaperone mobilization extends to other Hsp90 family members such as Grp94 (endoplasmic reticulum) and TRAP1 (mitochondrial form). Such approaches should also allow study of these phenomena using lower acrolein and drug concentrations than those used in the present study. Moreover, because Western blotting analysis of Hsp90 captured from acrolein- and hydralazine-treated cells suggested that adduct trapping actually occurred on both the monomeric and high-mass forms of Hsp90 (Fig. 9), future work should explore whether these reactions directly participate in Hsp90 mobilization and/or activation. Another issue to be addressed is whether, after oral dosing with hydralazine, sufficient free drug survives first-pass clearance in the gastrointestinal tract and liver, as well as spontaneous carbonyl-trapping reactions in circulating blood, to permit reactions with adducted proteins within remote tissues. Such work could, therefore, establish whether adduct trapping occurs in body tissues or blood proteins during short-term or chronic dosing with low doses of hydralazine that do not induce intolerable cardiovascular changes.

In conclusion, the present study identifies chaperone Hsp90 mobilization as a novel consequence of adduct trapping by nuclophilic drugs in cells that are subjected to carbonyl stress. Our provisional hypothesis proposes that by enhancing the “steric bulk” of carbonyl-adducted proteins, adduct-trapping drugs facilitate subcellular chaperone mobilization during carbonyl stress. This novel mechanism of drug action may be relevant to diverse diseases in which protein carbonylation occurs (Dalle-Donne et al., 2006), including important neurodegenerative disorders in which molecular chaperones are already thought to mitigate pathogenic neuronal loss (Aridon et al., 2011; Salmen et al., 2011). An ability to boost chaperone availability within cells containing damaged proteins raises the possibility of novel therapeutic approaches in these conditions, thereby extending encouraging results obtained for carbonyl scavengers in animal models of human neurodegeneration (Davies et al., 2011). The currency of this novel drug mechanism might be further increased by the finding that acrolein is a major contributor to age-related protein damage within the cardiac mitochondrial proteome of aging rats (Chavez et al., 2011).

Acknowledgments

We thank Simon Pyke (University of Adelaide) for helpful discussions concerning chemical mechanisms and Jay Steer (University of Western Australia) for helpful discussions concerning chaperone biochemistry.

Authorship Contributions

Participated in research design: Burcham.

Conducted experiments: Raso and Kaminskas.

Contributed new reagents or analytic tools: Burcham.

Performed data analysis: Burcham.

Wrote or contributed to the writing of the manuscript: Burcham and Kaminskas.

References


Address correspondence to: Philip C. Burcham, Pharmacology and Anaesthesiology Unit, School of Medicine and Pharmacology, University of Western Australia, Nedlands, WA 6009, Australia. E-mail: philip.burcham@uwa.edu.au